$285M
The private financing round was led by TCGX and Aisling Capital to fund clinical trials and commercial planning.
CP
COMPASS Pathways
Developing synthetic psilocybin formulations for treatment resistant mental health conditions.
London, UK—Founded 2016
$285MTotal raised
A London based biotechnology enterprise developing psilocybin therapies for mental health conditions.
Categories
Founders
GG
George Goldsmith
Lars Wilde
Lars co-founded several ventures, including Compass Pathways, Pangea Bio, Kadence Bio, and ELVT Labs. He also operates as an angel and early-stage investor.
LinkedInEM
Ekaterina Malievskaia
Ekaterina co-founded COMPASS Pathways, where she has served as chief innovation officer and head of research and development. She also spent seven years on the company board of directors.
LinkedIn